Good to hear the shift in focus to one of the comp
Post# of 30066
Posted On: 10/01/2015 1:23:48 PM
Good to hear the shift in focus to one of the company's most valuable short and long-term assets. There is a reason why ESS was valued at $1.8 Billion four years ago, even before DoD backing, ODD, IND, Phase 2 trial starting, other orphans, potential PRV(s) valued at $300M each, etc. Hats off to management for untangling the legal mess so this product can be brought to market now.
http://www.regenicin.com/news/complaint_2013_09_30.pdf
Quote:
Additionally, in 2010 Vectoris/Regenicin was valued at One Billion, Eight Hundred Million Dollars ($1,800,000,000.00). However, as of July 2012, Regenicin was valued at One Hundred Fifty-Seven Million Dollars ($157,000,000.00). Accordingly, Regenicin has been damaged in the amount of One Billion, Six Hundred Forty-Three Million Dollars ($1,643,000,000.00).
http://www.regenicin.com/news/complaint_2013_09_30.pdf
(0)
(0)